BTIG Reiterates Buy Rating on Oruka Therapeutics (ORKA): 'Commercial Precedents Continue to Read Through Positively to ORKA-001/2'

BTIG analyst Julian Harrison reiterated a Buy rating and $73.00 price target on Oruka Therapeutics (NASDAQ: ORKA)

The analyst commented, "4Q25 - EVERLAST-A (ORKA-001 in PsO Phase 2a) 16wk Induction Data Expected in 2Q26 with Long-Term Data in 2H26. Strong Growth from Commercial Precedents Continue to Read Through Positively to ORKA-001/2... Following enrollment completion in December 2025, Phase 2a ORKA-001 (anti-IL-23 mAb) 16wk data (EVERLAST-A) in moderate-to-severe PsO are expected in 2Q26 (previously 2H26). Longer-term data, including 28wk results for all patients and 52wk follow-up for a portion of patients, are expected in 2H26. Enrollment for the Phase 2b ORKA-001 trial in moderate-to-severe PsO (EVERLASTB) remains ongoing, with data anticipated in 2027."

For an analyst ratings summary and ratings history on Oruka Therapeutics click here. For more ratings news on Oruka Therapeutics click here.

Shares of Oruka Therapeutics closed at $31.99 yesterday.

You May Also Be Interested In

• Supreme Court declines to block Texas law requiring age verification and parental consent to download apps
• Unum Group (UNM) PT Raised to $106 at Evercore ISI
• B.Riley on Opus Genetics (IRD): 'we remain buyers'